Worp Nathalie, Koopmans Marion P G, Fouchier Ron A M, Oude Munnink Bas B
Erasmus MC, afd. Viroscience, Rotterdam.
Contact: Bas B. Oude Munnink (
Ned Tijdschr Geneeskd. 2021 Nov 30;165:D6496.
Almost two years after the introduction of SARS-CoV-2, it has become clear that the virus is unlikely to disappear any time soon. It is also clear that the virus mutates, resulting in specific variants of SARS-CoV-2. The exact implications of these variants are being investigated but it is likely that they have a selective advantage over previously circulating variants. It is possible that SARS-CoV-2 will mutate in the coming years to such an extent that existing vaccines do not offer sufficient protection against hospitalizations in the general population. At present, the protection of current vaccines against infection is observed to be reduced by the emergence of variants but remains high against hospitalizations and severe disease. Booster vaccinations are currently advised for specific risk groups where the regular vaccination schedule leads to an insufficient immune response, and are being considered for people in old age where the vaccine effectiveness is lower.
在新型冠状病毒(SARS-CoV-2)出现近两年后,情况已很明显,该病毒短期内不太可能消失。同样明显的是,该病毒会发生变异,从而产生SARS-CoV-2的特定变体。这些变体的确切影响正在研究中,但它们可能比先前传播的变体具有选择性优势。未来几年,SARS-CoV-2有可能发生极大程度的变异,以至于现有疫苗无法为普通人群提供足够的住院防护。目前观察到,变体的出现降低了现有疫苗对感染的防护效果,但对住院和重症疾病仍有很高的防护作用。目前建议针对常规疫苗接种方案导致免疫反应不足的特定风险群体进行加强接种,并正在考虑为疫苗效力较低的老年人进行加强接种。